Triple-negative breast cancer (TNBC) is an aggressive type of cancer but lacks targeted therapy methods such as hormone therapy due to the low expression of three primary receptors (ER, PR, and HER2). This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.